Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:33am, Monday, 30'th Oct 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Viatris stock has no real catalysts; greater downside risk: analysts
03:19pm, Monday, 23'rd Oct 2023
Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities analysts. In an update to clients, they downgrade
Viatris: Get Paid 5%, Before Growth Materializes
10:00am, Friday, 20'th Oct 2023
VTRS lost its Humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the former similarly losing another growth prospects in Wegovy.
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
09:15am, Friday, 13'th Oct 2023
Viatris is advancing in its plan to become leaner and pay off its debt. To do so, it's offloading a trio of non-core business segments.
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
09:29am, Tuesday, 10'th Oct 2023
PITTSBURGH , Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets.
2 Top Value Stocks to Buy in October
09:45am, Sunday, 08'th Oct 2023
Value stocks should perk up if the Federal Reserve decides to maintain high interest rates in 2024. Philip Morris and Viatris are two plays that ought to benefit from this value tilt.
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
08:15am, Sunday, 08'th Oct 2023
Medtronic offers impressive innovation, a strong position in healthcare, and an outstanding dividend history. Viatris is undergoing important changes that should lead to stronger financial results in
Drugmaker Viatris to divest some of its businesses
05:18pm, Sunday, 01'st Oct 2023
Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Active Pharmaceutical Ingredients (API) business. It re
Could Viatris Stock Help You Become a Millionaire?
07:58am, Saturday, 30'th Sep 2023
Viatris has a broad business that gives it many growth opportunities to pursue. The company is focusing on launching many products that can generate billions in revenue in the future.
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
12:02pm, Thursday, 28'th Sep 2023
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
Viatris and Ocuphire Pharma get FDA green light for eye treatment
08:21am, Wednesday, 27'th Sep 2023
Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
09:18am, Thursday, 14'th Sep 2023
High-yielding stocks can give you extra cash to help offset the impact of inflation. Many stocks are yielding far higher than 4%, including Viatris, Verizon, and Altria.
Why 5%-Yielding Viatris Hasn't Doubled Yet
06:07am, Thursday, 14'th Sep 2023
Viatris is a healthcare corporation formed through a merger, with a diversified global portfolio and a focus on ophthalmology, gastrointestinal, and dermatology therapeutic areas. Despite its elevated
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
12:47pm, Wednesday, 06'th Sep 2023
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
12:02pm, Tuesday, 05'th Sep 2023
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
